News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CymaBay Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update



8/11/2017 11:20:55 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
NEWARK, Calif., Aug. 10, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced financial results and a corporate update for the three and six months ended June 30, 2017.

“We reached a significant clinical milestone last month with the announcement of positive interim data from our ongoing Phase 2 clinical trial of seladelpar in patients with primary biliary cholangitis, or PBC,” said Sujal Shah, Interim President and Chief Executive Officer of CymaBay. “These results underscore the potent anti-cholestatic and anti-inflammatory effects of seladelpar.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES